Biohaven (BHVN) Fundamental Analysis: Revenue, Earnings & Valuation

2.63 / 10

Underperform

Fundamental rating is Underperform with a 2.6/10 score. Strengths include strong interest coverage and favorable Revenue‑MV, but liabilities ratio and PB‑ROE are weak. Inventory turnover and revenue growth are moderate, overall reflecting fragile financial health.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score3/3

Weight71.48%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.98%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-8.15%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value29.03

Score1/3

Weight-11.41%

1M Return-1.69%

PB-ROE

Value1.46

Score0/3

Weight24.08%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value1.12

Score3/3

Weight6.25%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-8.28%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.40%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-7.83%

1M Return-1.13%

Asset-MV

Value-0.55

Score0/3

Weight32.48%

1M Return4.00%

Is BHVN undervalued or overvalued?

BHVN scores 2.63/10 on fundamentals and holds a Premium valuation at present. Backed by its -310.75% ROE, 0.00% net margin, -1.70 P/E ratio, 24.18 P/B ratio, and 26.08% earnings growth, these metrics solidify its Underperform investment rating.